{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:10072"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:10072","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"Investigating the pharmacology of novel 5-HT3 receptor ligands; with the potential to treat neuropsychiatric and gastrointestinal disorders","abstract":"The 5-hydroxytryptamine (5-HT; serotonin) 5-HT3 receptor is an excitatory ligand-gated ion channel expressed in for example the brain and the gastrointestinal tract. Two major subtypes of the receptor have been studied in the most detail; the homomeric 5-HT3A receptor and the heteromeric 5-HT3AB receptor. 5-HT3 receptor antagonists are used clinically to treat chemotherapy induced and post-operative nausea and vomiting, and demonstrate symptomatic relief in diarrhoea-predominant irritable bowel syndrome (IBS-d); but unfortunately, these medications cause adverse effects such as constipation or rarely ischemic colitis in the latter condition. This study has characterised the pharmacology of two structurally distinct 5-HT3 receptor partial agonists (vortioxetine and CSTI-300); and identified the unique binding properties of the cryptic orthosteric modulator 5-chloroindole (Cl-indole) for the human (h) 5-HT3 receptor. Vortioxetine is a multi-modal antidepressant, which displays affinity for the 5-HT transporter as well as a multitude of 5-HT receptors, including the 5-HT3 receptor. The first part of this study has identified vortioxetine as a relatively high affinity, competitive 5-HT3 receptor partial agonist with an intrinsic efficacy of approximately 40-50% that of 5-HT. Given the safety of vortioxetine in patients, it has the potential to be trialled in other conditions for which 5-HT3 receptor antagonists demonstrate efficacy but cause adverse effects, such as IBS-d or even schizophrenia. The second section of this study has identified CSTI-300 as a selective, high affinity 5-HT3 receptor partial agonist (intrinsic activity 30-40% that of 5-HT). Moreover, in a rodent model of IBS-d, CSTI-300 demonstrated comparable efficacy to alosetron, a 5-HT3 receptor antagonist with established efficacy in treating IBS-d. CSTI-300 is predicted to be able to relieve symptoms of IBS-d in patients without eliciting the side effect profile associated with 5-HT3 receptor antagonism. The final part of this study has demonstrated that the binding mechanism of Cl-indole for the 5-HT3A receptor is modulated by 5-HT3 receptor agonists, but not 5-HT3 receptor antagonists. This could have implications in designing 5-HT3 receptor allosteric ligands for potentially treating conditions such as IBS-d.","abstract_html":"The 5-hydroxytryptamine (5-HT; serotonin) 5-HT3 receptor is an excitatory ligand-gated ion channel expressed in for example the brain and the gastrointestinal tract. Two major subtypes of the receptor have been studied in the most detail; the homomeric 5-HT3A receptor and the heteromeric 5-HT3AB receptor. 5-HT3 receptor antagonists are used clinically to treat chemotherapy induced and post-operative nausea and vomiting, and demonstrate symptomatic relief in diarrhoea-predominant irritable bowel syndrome (IBS-d); but unfortunately, these medications cause adverse effects such as constipation or rarely ischemic colitis in the latter condition. This study has characterised the pharmacology of two structurally distinct 5-HT3 receptor partial agonists (vortioxetine and CSTI-300); and identified the unique binding properties of the cryptic orthosteric modulator 5-chloroindole (Cl-indole) for the human (h) 5-HT3 receptor. Vortioxetine is a multi-modal antidepressant, which displays affinity for the 5-HT transporter as well as a multitude of 5-HT receptors, including the 5-HT3 receptor. The first part of this study has identified vortioxetine as a relatively high affinity, competitive 5-HT3 receptor partial agonist with an intrinsic efficacy of approximately 40-50% that of 5-HT. Given the safety of vortioxetine in patients, it has the potential to be trialled in other conditions for which 5-HT3 receptor antagonists demonstrate efficacy but cause adverse effects, such as IBS-d or even schizophrenia. The second section of this study has identified CSTI-300 as a selective, high affinity 5-HT3 receptor partial agonist (intrinsic activity 30-40% that of 5-HT). Moreover, in a rodent model of IBS-d, CSTI-300 demonstrated comparable efficacy to alosetron, a 5-HT3 receptor antagonist with established efficacy in treating IBS-d. CSTI-300 is predicted to be able to relieve symptoms of IBS-d in patients without eliciting the side effect profile associated with 5-HT3 receptor antagonism. The final part of this study has demonstrated that the binding mechanism of Cl-indole for the 5-HT3A receptor is modulated by 5-HT3 receptor agonists, but not 5-HT3 receptor antagonists. This could have implications in designing 5-HT3 receptor allosteric ligands for potentially treating conditions such as IBS-d.","abstract_has_math":false,"creators":["Roberts, Alexander"],"institution":"University of Birmingham","degree_name":"d_ph","degree_level":"d_ph","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2020,"date_issued":"2020-07","date_published":"2020-07","updated_at":"2026-11-19T09:31:02Z","subjects":["QP Physiology","RM Therapeutics. Pharmacology"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/10072/7/Roberts2020PhD.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A10072","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["other"]},{"key":"dc:creator","label":"Author","values":["Roberts, Alexander"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2020-07-01"]},{"key":"dc:date.issued","label":"Date","values":["2020-07"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","Institute of Clinical Sciences"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/10072/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["d_ph"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["d_ph"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["QP Physiology","RM Therapeutics. Pharmacology"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/10072/7/Roberts2020PhD.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["The 5-hydroxytryptamine (5-HT; serotonin) 5-HT3 receptor is an excitatory ligand-gated ion channel expressed in for example the brain and the gastrointestinal tract. Two major subtypes of the receptor have been studied in the most detail; the homomeric 5-HT3A receptor and the heteromeric 5-HT3AB receptor. 5-HT3 receptor antagonists are used clinically to treat chemotherapy induced and post-operative nausea and vomiting, and demonstrate symptomatic relief in diarrhoea-predominant irritable bowel syndrome (IBS-d); but unfortunately, these medications cause adverse effects such as constipation or rarely ischemic colitis in the latter condition. This study has characterised the pharmacology of two structurally distinct 5-HT3 receptor partial agonists (vortioxetine and CSTI-300); and identified the unique binding properties of the cryptic orthosteric modulator 5-chloroindole (Cl-indole) for the human (h) 5-HT3 receptor. Vortioxetine is a multi-modal antidepressant, which displays affinity for the 5-HT transporter as well as a multitude of 5-HT receptors, including the 5-HT3 receptor. The first part of this study has identified vortioxetine as a relatively high affinity, competitive 5-HT3 receptor partial agonist with an intrinsic efficacy of approximately 40-50% that of 5-HT. Given the safety of vortioxetine in patients, it has the potential to be trialled in other conditions for which 5-HT3 receptor antagonists demonstrate efficacy but cause adverse effects, such as IBS-d or even schizophrenia. The second section of this study has identified CSTI-300 as a selective, high affinity 5-HT3 receptor partial agonist (intrinsic activity 30-40% that of 5-HT). Moreover, in a rodent model of IBS-d, CSTI-300 demonstrated comparable efficacy to alosetron, a 5-HT3 receptor antagonist with established efficacy in treating IBS-d. CSTI-300 is predicted to be able to relieve symptoms of IBS-d in patients without eliciting the side effect profile associated with 5-HT3 receptor antagonism. The final part of this study has demonstrated that the binding mechanism of Cl-indole for the 5-HT3A receptor is modulated by 5-HT3 receptor agonists, but not 5-HT3 receptor antagonists. This could have implications in designing 5-HT3 receptor allosteric ligands for potentially treating conditions such as IBS-d."]},{"key":"dc:format","label":"Dc Format","values":["text"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public"]},{"key":"dc:title","label":"Title","values":["Investigating the pharmacology of novel 5-HT3 receptor ligands; with the potential to treat neuropsychiatric and gastrointestinal disorders"]}]}],"canonical_facts":{"dc:contributor.sponsor":["other"],"dc:creator":["Roberts, Alexander"],"dc:date":["2020-07-01"],"dc:date.issued":["2020-07"],"dc:description.abstract":["The 5-hydroxytryptamine (5-HT; serotonin) 5-HT3 receptor is an excitatory ligand-gated ion channel expressed in for example the brain and the gastrointestinal tract. Two major subtypes of the receptor have been studied in the most detail; the homomeric 5-HT3A receptor and the heteromeric 5-HT3AB receptor. 5-HT3 receptor antagonists are used clinically to treat chemotherapy induced and post-operative nausea and vomiting, and demonstrate symptomatic relief in diarrhoea-predominant irritable bowel syndrome (IBS-d); but unfortunately, these medications cause adverse effects such as constipation or rarely ischemic colitis in the latter condition. This study has characterised the pharmacology of two structurally distinct 5-HT3 receptor partial agonists (vortioxetine and CSTI-300); and identified the unique binding properties of the cryptic orthosteric modulator 5-chloroindole (Cl-indole) for the human (h) 5-HT3 receptor. Vortioxetine is a multi-modal antidepressant, which displays affinity for the 5-HT transporter as well as a multitude of 5-HT receptors, including the 5-HT3 receptor. The first part of this study has identified vortioxetine as a relatively high affinity, competitive 5-HT3 receptor partial agonist with an intrinsic efficacy of approximately 40-50% that of 5-HT. Given the safety of vortioxetine in patients, it has the potential to be trialled in other conditions for which 5-HT3 receptor antagonists demonstrate efficacy but cause adverse effects, such as IBS-d or even schizophrenia. The second section of this study has identified CSTI-300 as a selective, high affinity 5-HT3 receptor partial agonist (intrinsic activity 30-40% that of 5-HT). Moreover, in a rodent model of IBS-d, CSTI-300 demonstrated comparable efficacy to alosetron, a 5-HT3 receptor antagonist with established efficacy in treating IBS-d. CSTI-300 is predicted to be able to relieve symptoms of IBS-d in patients without eliciting the side effect profile associated with 5-HT3 receptor antagonism. The final part of this study has demonstrated that the binding mechanism of Cl-indole for the 5-HT3A receptor is modulated by 5-HT3 receptor agonists, but not 5-HT3 receptor antagonists. This could have implications in designing 5-HT3 receptor allosteric ligands for potentially treating conditions such as IBS-d."],"dc:format":["text"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/10072/7/Roberts2020PhD.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","Institute of Clinical Sciences"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/10072/"],"dc:subject":["QP Physiology","RM Therapeutics. Pharmacology"],"dcterms:accessrights":["public"],"dc:title":["Investigating the pharmacology of novel 5-HT3 receptor ligands; with the potential to treat neuropsychiatric and gastrointestinal disorders"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["d_ph"],"dc:type.qualificationname":["d_ph"]},"updated_at":"2026-11-19T09:31:02Z"}